A comparison of intervention with losartan or captopril in acute myocardial infarction

European Journal of Heart Failure

Volumn 2, Issue 1, 2000, Pages 91-100

  Spinar, J ^a   Vitovec, J ^a   Spinarova, L ^a   Pluhacek, L ^a   Fischerova, B ^a   Toman, J ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Angiotensin II receptor; Captopril; Losartan; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LOSARTAN; NITRATE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE WALL MOTION; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 0034034426     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00070-7     Document Type: Article

References (42)

1. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 339:1992;753-770.
2. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 336(23):1997;1621-1628.
3. Guidelines for the Management of Patients with Acute Myocardial Infarction. Executive summary. Circulation 1996;94:2341-2350.
4. Kingma J.H., van Gilst W.H., Peels C.H., Dambrink J.-H.E., Verheugt F.W.A., Wielenga R.P. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J. 15:1994;898-907.
5. Pfeffer J.M. Progressive ventricular dilation in experimental myocardial infarction and its attenuation by angiotensin-converting enzyme inhibition. Am J Cardiol. 68:1991;17D-25D.
6. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet. 280:1991;181-193.
7. Pfeffer M.A., Braunwald E., Moye L.A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 327:1992;669-677.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
9. Effects of lisinopril and transdermal glyceryl trinitrate singly or together on 6-week mortality and ventricular function after myocardial infarction. Lancet. 343:1994;1115-1122.
10. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected myocardial infarction. Lancet. 345:1995;669-685.
11. Braunwald E. ACE inhibitors: a cornerstone of the treatment of heart failure. N Engl J Med. 325:1991;351-353.
12. Dickstein K., Gottlieb S., Fleck E. et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. Hypertension. 12(suppl 2):1994;S31-S35.
13. Dickstein K., Chang P., Willenheimer R. et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26(2):1995;438-445.
14. Pitt B., Segal R., Martinez F.A. et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet. 349:1997;747-752.
15. Goldberg I.A., Dunlay C.M., Sweet S.C. Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. Hypertension. 13(Suppl 1):1995;S77-S80.
16. Spinar J., VÌtovec J., Blaha M., Spinarova L., Stejfa M., Toman J. Radiological changes in heart failure. Cor Vasa. 34:1992;88-99.
17. Foy S.G., Crozier I.G., Richards A.M. et al. Neurohumoral changes after myocardial infarction: relationships with hemodynamic indices and effects of ACE inhibition. Eur Heart J. 16:1995;770-778.
18. Rouleau J.L., Moyé L.A., de Champlain J. et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol. 68:1991;80D-86D.
19. McAlpine H.M., Cobbe S.M. Neuroendocrine changes in acute myocardial infarction. Am J Med. 84(Suppl 3A):1988;61-65.
20. Pfeffer M.A., Braunwald E. Ventricular remodelling after myocardial infarction. Experimental observation and clinical implication. Circulation. 81:1990;1161-1172.
21. Weisman H.F., Bush D.E., Mannisi J.A., Weisfeldt M.L., Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation. 78:1988;186-201.
22. Vracko R., Thorning D., Frederickson R.G. Connective tissue cells in healing rat myocardium. Am J Pathol. 134:1989;993-1006.
23. Eaton L.W., Weiss J.L., Bulkley B.H., Garrison J.B., Weisfeldt M.D. Regional cardiac dilatation after acute myocardial infarction. N Engl J Med. 300:1979;57-62.
24. Erlebacher J.A., Weiss J.L., Eaton L.W., Kallman C., Weisfeldt M.D., Bulkley B.H. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 49:1982;1120-1126.
25. Schuster E.H., Bulkley B.H. Expansion of transmural myocardial infarction: a pathophysiological factor in cardiac rupture. Circulation. 60:1979;1532-1538.
26. Johnston I.C. Angiotensin receptor antagonists: focus on losartan. Lancet. 346:1995;1403-1407.
27. Torp-Pedersen C., Kober L., Burchardt H. The place of angiotensin-converting enzyme inhibition after acute myocardial infarction. Am Heart J. 134(2):1997;S25-S29.
28. Pfeffer M.A. Angiotensin converting enzyme inhibition in heart failure: benefit and perspective. Am Heart J. 126:1993;789-793.
29. Spinar J., VÌtovec J., Spac J., Blaha M., Spinarova L., Toman J. Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. Int J Cardiol. 56:1996;283-288.
30. Crozier I., Ikram H. The acute and chronic effects of losartan in heart failure. J Hypertens. 13:1995;S59-S61.
31. Tikkanen I., Omvik P., Jensen H.E. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 13:1995;1343-1351.
32. Holwerda N.J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 14:1996;1147-1151.
33. Smith J.F.M., Van Krimpon C., Schomaker R.G. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis and interstitial collagen content. J Cardiovasc Pharmacol. 20:1992;772-778.
34. Liu Y.H., Yang X.P., Sharov V.G. et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1-receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 99:1997;1926-1935.
35. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 327:1992;678-684.
36. Lew A.S., Laramee P., Cercek B., Shah P.K., Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation. 72:1985;1321-1326.
37. Regitz-Zagrosek V., Neuss M., Fleck E. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Eur Heart J. 16(Suppl N):1995;86-91.
38. Pfeffer M.A., Greaves S.C., Arnold J.M.O. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reduction Therapy Trial. Circulation. 95:1997;2643-2651.
39. Guidelines for the early management of patients with acute myocardial MI. ACC/AHA Task Force report. J Am Coll Cardiol 1990;16:249-292.
40. Sladek T., Sladek J., Kolar F. et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res. 31:1995;568-576.
41. Packer M, for the ATLAS Study Investigators. ATLAS oral presentation, American College of Cardiology. Atlanta, Georgia, USA, 1998.
42. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure in clinical practice? J Am Coll Cardiol. 28(5):1996;1323-1327.